Core Points - The company is planning a change in control, potentially moving from a state of no actual controller to having one, involving major shareholder Ge Hang and Hangzhou Genghao Zhito Management Consulting Partnership [1] - The company's stock will be suspended from trading starting November 10, 2025, for a period not exceeding two trading days [1] Company Overview - Founded in 1997, the company is one of the early entrants in the medical and health information technology sector in China, focusing on the construction, research, and service innovation of health information systems [1] - The company has implemented nearly 20,000 health information construction projects, serving over 7,000 industry users, with public health projects covering more than 370 districts and counties nationwide, accumulating approximately 300 million resident health records [1] Financial Performance - For the first half of 2025, the company reported total revenue of 577 million yuan, a year-on-year decrease of 20.65% [1] - The net loss attributable to shareholders for the same period was 80.55 million yuan, compared to a loss of 27.37 million yuan in the previous year, indicating an expanded loss [1] Industry Metrics - In the first half of 2025, the internet hospital prescription flow reached 190,000 orders, with a 140% increase in traditional Chinese medicine prescription collaborations [2] - The company has partnered with over 250 commercial insurance institutions and aggregated payment merchants totaling 2,000, with 48 million new transactions and a transaction volume of 8.5 billion yuan [2] - Cloud nursing collaborations involve over 250 institutions, with more than 7,600 nurses and 93,800 orders processed [2]